<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00777907</url>
  </required_header>
  <id_info>
    <org_study_id>CLP-0004</org_study_id>
    <nct_id>NCT00777907</nct_id>
  </id_info>
  <brief_title>Complete Occlusion of Coilable Aneurysms</brief_title>
  <acronym>COCOA</acronym>
  <official_title>Complete Occlusion of Coilable Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chestnut Medical Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chestnut Medical Technologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the safety and effectiveness of Pipeline Embolization Device to coil embolization&#xD;
      for the treatment of coilable wide-necked intracranial aneurysms&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness: Proportion of subjects whose target aneurysm shows complete occlusion on angiogram with &lt;=50% stenosis of the parent artery. Safety: Proportion of subjects with ipsilateral major stroke or neurologic death.</measure>
    <time_frame>180 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of complete target aneurysm occlusion</measure>
    <time_frame>1, 3 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ipsilateral major stroke</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in modified Rankin scale (MRS)</measure>
    <time_frame>180 days, 1, 3 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of device-related adverse events</measure>
    <time_frame>180 days, 1, 3 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in neurologic signs or symptoms related to the target aneurysm</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <arm_group>
    <arm_group_label>Coil embolization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placement of bare platinum coils into the target aneurysm with balloon remodeling allowed. Stents are not allowed in this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pipeline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placement of 1 or more Pipeline Embolization Device(s)(PED) into the parent artery at the target aneurysm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pipeline Embolization Device (PED)</intervention_name>
    <description>1 or more PEDs placed in the parent artery of the affected aneurysm via endovascular approach.</description>
    <arm_group_label>Pipeline</arm_group_label>
    <other_name>Pipeline Embolization Device, PED</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coil embolization</intervention_name>
    <description>Placement of bare platinum coils into the target aneurysm with balloon remodeling allowed.</description>
    <arm_group_label>Coil embolization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 21 to 75 years, inclusive&#xD;
&#xD;
          -  Patient has a single target IA that:&#xD;
&#xD;
               1. is located in the following regions of the internal carotid artery: i.&#xD;
                  Paraophthalmic (including paraclinoid, ophthalmic and hypophyseal segments) ii.&#xD;
                  Cavernous iii. Petrous&#xD;
&#xD;
               2. is saccular&#xD;
&#xD;
               3. has a parent vessel with diameter 2.5-5.0 mm&#xD;
&#xD;
          -  If target IA has a neck &gt;4 mm, at least 2 of 3 members of an independent expert&#xD;
             committee (IEC) have confirmed that coil embolization with optional adjunctive&#xD;
             techniques** has a very high likelihood of procedural success (i.e., coil placement&#xD;
             and retention)&#xD;
&#xD;
          -  Subject has provided written informed consent using the IRB-approved consent form&#xD;
&#xD;
          -  Subject has the necessary mental capacity to participate and is willing and able to&#xD;
             comply with protocol requirements&#xD;
&#xD;
               -  ** Adjunctive techniques include intravascular balloons [&quot;balloon remodeling&quot;],&#xD;
                  3D coils, dual catheter techniques.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Target IA has BOTH neck &gt;4 mm AND size (maximum fundus diameter) &gt;10 mm&#xD;
&#xD;
          -  More than one IA requires treatment in the next 6 months&#xD;
&#xD;
          -  Subarachnoid hemorrhage in the past 60 days&#xD;
&#xD;
          -  Any intracranial hemorrhage in the last 42 days&#xD;
&#xD;
          -  Major surgery in the last 42 days&#xD;
&#xD;
          -  Coils in place in the target IA&#xD;
&#xD;
          -  Unstable neurologic deficit (i.e., any worsening of clinical condition in the last 30&#xD;
             days)&#xD;
&#xD;
          -  Known irreversible bleeding disorder&#xD;
&#xD;
          -  Platelet count &lt; 100 x 103 cells/mm3 or known platelet dysfunction&#xD;
&#xD;
          -  Inability to tolerate, documented evidence of adverse reaction or contraindication to&#xD;
             study medications&#xD;
&#xD;
          -  Prior stent placement at target site&#xD;
&#xD;
          -  Contraindication to CT scan AND MRI&#xD;
&#xD;
          -  Known allergy to contrast used in angiography that cannot be medically controlled&#xD;
&#xD;
          -  Known severe allergy to platinum or cobalt/chromium alloys&#xD;
&#xD;
          -  Relative contraindication to angiography (e.g., serum creatinine &gt; 2.5 mg/dL)&#xD;
&#xD;
          -  Woman of child-bearing potential who cannot provide a negative pregnancy test&#xD;
&#xD;
          -  Evidence of active infection at the time of treatment&#xD;
&#xD;
          -  Other known conditions of the heart, blood, brain or intracranial vessels that carry a&#xD;
             high risk of neurologic events (e.g., severe heart failure, atrial fibrillation, known&#xD;
             carotid stenosis)&#xD;
&#xD;
          -  Current use of cocaine or other illicit substance&#xD;
&#xD;
          -  Any comorbid disease or condition expected to compromise survival or ability to&#xD;
             complete follow-up assessments to 180 days&#xD;
&#xD;
          -  Extracranial stenosis greater than 50% in the carotid artery&#xD;
&#xD;
          -  Intracranial stenosis greater than 50% in the treated vessel&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Fiorella, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barrow Neurologic Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Stony Brook</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>October 20, 2008</study_first_submitted>
  <study_first_submitted_qc>October 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2008</study_first_posted>
  <last_update_submitted>August 5, 2015</last_update_submitted>
  <last_update_submitted_qc>August 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neurovascular embolization</keyword>
  <keyword>therapeutic embolization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

